<DOC>
	<DOCNO>NCT02163525</DOCNO>
	<brief_summary>This Post Market study conduct compare direct indirect cost three approach ( GFA , myomectomy , uterine artery embolization ) treatment symptomatic uterine fibroid . In addition , data study use satisfy requirement United States Food Drug Administration 's 522 ( post market surveillance ) order .</brief_summary>
	<brief_title>Post Market TRUST - U.S.A. Study</brief_title>
	<detailed_description>The purpose study 1 ) evaluate economic burden , safety outcome three uterine-conserving treatment alternative symptomatic uterine fibroid : myomectomy , uterine artery embolization ( UAE ) , global fibroid ablation ( GFA ) use Acessa™ System , 2 ) meet requirement U.S. Food Drug Administration 's 522 Order post market surveillance In study , subject symptomatic uterine fibroid randomize one three uterine-conserving treatment base local standard care .</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>Are ≥ 18 year old menstruating Have symptomatic uterine fibroid Have uterine size ≤ 16 gestational week determine pelvic exam Have fibroid less 10 cm diameter Desire uterine conservation Have normal Pap smear within past 36 month define `` untreated cervical malignancy dysplasia . '' Are willing able comply study test , procedure , assessment tool Are capable provide informed consent . Have contraindication laparoscopic surgery and/or general anesthesia . Are expect high risk , know , significant intraabdominal adhesion ( defined adhesion would require extensive dissection mobilize view surface uterus ) Patients require major elective concomitant procedure ( e.g. , hernia repair ) Are pregnant lactate Have take depot gonadotropin release hormone ( GnRh ) agonist within three month prior screen procedure Have implant intrauterine fallopian tube device contraception remove least 10 day prior treatment Have chronic pelvic pain know due uterine fibroid Have know suspected endometriosis Stage 3 4 , adenomyosis Have active history pelvic inflammatory disease Have history , evidence , gynecologic malignancy premalignancy within past five year Have pelvic radiation Have nonuterine pelvic mass 3 cm Have cervical myoma Have one completely intracavitary submucous fibroid ( Type 0 ) Type 0/1 submucous fibroid well treat via hysteroscopic method In medical judgment investigator participate study Are willing randomized treatment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Fibroids</keyword>
	<keyword>Myomas</keyword>
	<keyword>leiomyomata</keyword>
	<keyword>menorrhagia</keyword>
	<keyword>Acessa Procedure</keyword>
	<keyword>Radiofrequency Ablation ( RFA )</keyword>
	<keyword>GFA</keyword>
	<keyword>Acessa</keyword>
</DOC>